Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 5.70
INFI's Cash-to-Debt is ranked lower than
61% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 59.90 vs. INFI: 5.70 )
Ranked among companies with meaningful Cash-to-Debt only.
INFI' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.28  Med: 1918.61 Max: 13254
Current: 5.7
0.28
13254
Equity-to-Asset 0.63
INFI's Equity-to-Asset is ranked lower than
55% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. INFI: 0.63 )
Ranked among companies with meaningful Equity-to-Asset only.
INFI' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.03  Med: 0.65 Max: 0.94
Current: 0.63
-0.03
0.94
Piotroski F-Score: 3
Altman Z-Score: -4.12
Beneish M-Score: -4.33
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -39.50
INFI's Operating Margin % is ranked higher than
58% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -88.13 vs. INFI: -39.50 )
Ranked among companies with meaningful Operating Margin % only.
INFI' s Operating Margin % Range Over the Past 10 Years
Min: -144.7  Med: -91.69 Max: 22.94
Current: -39.5
-144.7
22.94
Net Margin % -39.11
INFI's Net Margin % is ranked higher than
57% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. INFI: -39.11 )
Ranked among companies with meaningful Net Margin % only.
INFI' s Net Margin % Range Over the Past 10 Years
Min: -153.81  Med: -68.67 Max: 28.35
Current: -39.11
-153.81
28.35
ROE % -46.05
INFI's ROE % is ranked lower than
57% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: -34.32 vs. INFI: -46.05 )
Ranked among companies with meaningful ROE % only.
INFI' s ROE % Range Over the Past 10 Years
Min: -123.36  Med: -41.36 Max: 27.59
Current: -46.05
-123.36
27.59
ROA % -19.29
INFI's ROA % is ranked higher than
60% of the 972 Companies
in the Global Biotechnology industry.

( Industry Median: -30.23 vs. INFI: -19.29 )
Ranked among companies with meaningful ROA % only.
INFI' s ROA % Range Over the Past 10 Years
Min: -44.77  Med: -27.61 Max: 16.29
Current: -19.29
-44.77
16.29
ROC (Joel Greenblatt) % -114.41
INFI's ROC (Joel Greenblatt) % is ranked higher than
63% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. INFI: -114.41 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
INFI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3156.78  Med: -543.5 Max: 418.86
Current: -114.41
-3156.78
418.86
3-Year Revenue Growth Rate 14.40
INFI's 3-Year Revenue Growth Rate is ranked higher than
66% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. INFI: 14.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
INFI' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -100  Med: -6.2 Max: 154.4
Current: 14.4
-100
154.4
3-Year EBITDA Growth Rate 16.80
INFI's 3-Year EBITDA Growth Rate is ranked higher than
67% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. INFI: 16.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
INFI' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -55.4  Med: 13.8 Max: 135.8
Current: 16.8
-55.4
135.8
3-Year EPS without NRI Growth Rate 15.50
INFI's 3-Year EPS without NRI Growth Rate is ranked higher than
72% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: -3.10 vs. INFI: 15.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
INFI' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -64  Med: 12.35 Max: 116
Current: 15.5
-64
116
GuruFocus has detected 2 Warning Signs with Infinity Pharmaceuticals Inc $INFI.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» INFI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

INFI Guru Trades in Q1 2016

Paul Tudor Jones 59,600 sh (New)
Steven Cohen Sold Out
Jim Simons 12,300 sh (-92.22%)
Eaton Vance Worldwide Health Sciences Fund 654,534 sh (-3.46%)
» More
Q2 2016

INFI Guru Trades in Q2 2016

Jim Simons 749,700 sh (+5995.12%)
Paul Tudor Jones 277,600 sh (+365.77%)
Eaton Vance Worldwide Health Sciences Fund Sold Out
» More
Q3 2016

INFI Guru Trades in Q3 2016

Jim Simons 1,860,900 sh (+148.22%)
Paul Tudor Jones 19,798 sh (-92.87%)
» More
Q4 2016

INFI Guru Trades in Q4 2016

Paul Tudor Jones 165,998 sh (+738.46%)
Jim Simons 1,700,000 sh (-8.65%)
» More
» Details

Insider Trades

Latest Guru Trades with INFI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:IMMVF, OTCPK:CTIX, NAS:KIN, OTCPK:HPPI, NAS:GNCA, NAS:ADVM, NAS:EGLT, NAS:ATHX, NAS:CXRX, NAS:VVUS, NAS:LPTX, NAS:CORI, NAS:ZFGN, OTCPK:MCUJF, NAS:PSTI, NAS:CDXC, NAS:CTIC, AMEX:PLX, NAS:EVGN, OTCPK:HSDT » details
Traded in other countries:I3F.Germany,
Infinity Pharmaceuticals Inc is a biopharmaceutical company engaged in discovering, developing & delivering medicines to people with difficult-to-treat diseases. Its primary product candidate is duvelisib, also known as IPI-145, an oral inhibitor.

Infinity Pharmaceuticals Inc was incorporated in California on March 22, 1995 under the name IRORI and, in 1998, it changed its name to Discovery Partners International, Inc., or DPI. In July 2000, it reincorporated in Delaware. On September 12, 2006, DPI completed a merger with the Company, pursuant to which a wholly-owned subsidiary of DPI merged with and into the Company. In addition, it changed its corporate name from Discovery Partners International, Inc. to Infinity Pharmaceuticals, Inc. The Company is a biopharmaceutical company engaged in discovering, developing and delivering medicines to patients with difficult-to-treat diseases. Its product candidate is duvelisib, also known as IPI-145, an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase, or PI3K, which is being evaluated for the treatment of hematologic malignancies, or blood cancers. The Company's product candidates, duvelisib and IPI-549 include DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Advanced Hematologic Malignancies consists of Duvelisib + Venetoclax, IPI-549: PI3K Gamma-Selective Inhibitor. As part of the DUETTS program in lymphoma, it is conducting DYNAMO, a Phase 2, open-label, single-arm monotherapy study evaluating the safety and efficacy of duvelisib dosed at 25 mg twice daily in 129 patients with iNHL. The FDA has granted orphan drug designation to duvelisib for the potential treatment of follicular lymphoma, and has granted fast track designation to the investigation of duvelisib for the treatment of patients with follicular lymphoma who have received at least two prior therapies. The Company has eight issued or allowed U.S. patents related to its duvelisib program, which expire on various dates between 2029 and 2032, excluding any patent term extension. It has three issued or allowed U.S. patents related to its PI3K gamma program, which expire on various dates between 2033 and 2034, excluding any patent term extension. In addition, it has approximately 275 patents and patent applications pending related to its PI3K programs.

Ratios

vs
industry
vs
history
Price-to-Owner-Earnings 2.50
INFI's Price-to-Owner-Earnings is ranked higher than
94% of the 143 Companies
in the Global Biotechnology industry.

( Industry Median: 29.18 vs. INFI: 2.50 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
INFI' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 1.02  Med: 9.77 Max: 154.41
Current: 2.5
1.02
154.41
PB Ratio 1.12
INFI's PB Ratio is ranked higher than
88% of the 1106 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. INFI: 1.12 )
Ranked among companies with meaningful PB Ratio only.
INFI' s PB Ratio Range Over the Past 10 Years
Min: 0.45  Med: 3.11 Max: 51.43
Current: 1.12
0.45
51.43
PS Ratio 4.04
INFI's PS Ratio is ranked higher than
74% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: 12.50 vs. INFI: 4.04 )
Ranked among companies with meaningful PS Ratio only.
INFI' s PS Ratio Range Over the Past 10 Years
Min: 0.55  Med: 3.82 Max: 60.95
Current: 4.04
0.55
60.95
Current Ratio 4.77
INFI's Current Ratio is ranked higher than
55% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. INFI: 4.77 )
Ranked among companies with meaningful Current Ratio only.
INFI' s Current Ratio Range Over the Past 10 Years
Min: 0.64  Med: 8.37 Max: 17.81
Current: 4.77
0.64
17.81
Quick Ratio 4.77
INFI's Quick Ratio is ranked higher than
56% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 3.91 vs. INFI: 4.77 )
Ranked among companies with meaningful Quick Ratio only.
INFI' s Quick Ratio Range Over the Past 10 Years
Min: 0.41  Med: 8.37 Max: 17.81
Current: 4.77
0.41
17.81
Days Sales Outstanding 5.50
INFI's Days Sales Outstanding is ranked higher than
91% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. INFI: 5.50 )
Ranked among companies with meaningful Days Sales Outstanding only.
INFI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.18  Med: 4.54 Max: 831.54
Current: 5.5
0.18
831.54

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.30
INFI's 3-Year Average Share Buyback Ratio is ranked higher than
86% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. INFI: -1.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
INFI' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -178.7  Med: -16.2 Max: -0.8
Current: -1.3
-178.7
-0.8

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1.81
INFI's Price-to-Net-Cash is ranked higher than
88% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: 5.89 vs. INFI: 1.81 )
Ranked among companies with meaningful Price-to-Net-Cash only.
INFI' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.85  Med: 2.87 Max: 38.43
Current: 1.81
0.85
38.43
Price-to-Net-Current-Asset-Value 1.53
INFI's Price-to-Net-Current-Asset-Value is ranked higher than
89% of the 879 Companies
in the Global Biotechnology industry.

( Industry Median: 5.57 vs. INFI: 1.53 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
INFI' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.74  Med: 2.69 Max: 398.67
Current: 1.53
0.74
398.67
Price-to-Tangible-Book 1.11
INFI's Price-to-Tangible-Book is ranked higher than
91% of the 1015 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. INFI: 1.11 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
INFI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.55  Med: 2.33 Max: 46.18
Current: 1.11
0.55
46.18
Price-to-Median-PS-Value 1.06
INFI's Price-to-Median-PS-Value is ranked lower than
62% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. INFI: 1.06 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
INFI' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.15  Med: 0.77 Max: 15.69
Current: 1.06
0.15
15.69
Earnings Yield (Greenblatt) % -219.37
INFI's Earnings Yield (Greenblatt) % is ranked lower than
95% of the 1203 Companies
in the Global Biotechnology industry.

( Industry Median: -9.03 vs. INFI: -219.37 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
INFI' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -263.49  Med: 75.9 Max: 857.3
Current: -219.37
-263.49
857.3

More Statistics

Revenue (TTM) (Mil) $118.5
EPS (TTM) $ -0.96
Beta2.57
Short Percentage of Float8.32%
52-Week Range $0.84 - 6.97
Shares Outstanding (Mil)49.73

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 18 90 55
EPS ($) -1.46 -1.34 -0.76 -0.76
EPS without NRI ($) -1.46 -1.34 -0.76 -0.76
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for INFI

Headlines

Articles On GuruFocus.com
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q/A) Mar 15 2011 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q/A) Mar 15 2011 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q/A) Mar 15 2011 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q) Aug 04 2010 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q) May 06 2010 
INFINITY PHARMACEUTICALS, INC. Reports Operating Results (10-Q) Aug 06 2009 
Infinity Pharmaceuticals Inc. Reports Operating Results (10-Q) May 06 2009 

More From Other Websites
Infinity Announces Promotion of Jeffery Kutok, M.D., Ph.D. to Chief Scientific Officer Feb 13 2017
Infinity to Present at the 2017 BIO CEO & Investor Conference Feb 06 2017
Faster FDA Approval Process Could Ignite These Biotech Stocks in 2017 Feb 02 2017
Infinity Presents Preclinical Data and Phase 1 Clinical Data on IPI-549 at PI3K Keystone Symposia... Jan 20 2017
INFINITY PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Jan 09 2017
Infinity Provides 2017 Goals and Financial Guidance Jan 09 2017
Don't Tell Anyone: Insiders Are Buying These Stocks Like Crazy Jan 08 2017
Infinity To Present At 35th Annual J.P. Morgan Annual Healthcare Conference Jan 05 2017
Infinity Announces Organizational Changes Jan 04 2017
INFINITY PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Jan 04 2017
Infinity Announces Organizational Changes Jan 04 2017
5 Stocks Insiders Love Right Now Dec 21 2016
How Health Insurance Innovations Inc (HIIQ) Stacks Up Against Its Peers Dec 19 2016
Is Infinity Pharmaceuticals Inc. (INFI) a Good Stock to Buy? Dec 10 2016
INFINITY PHARMACEUTICALS, INC. Financials Nov 17 2016
Infinis plc announces second quarter results for year ending 31.03.17 £350m 7% Senior Notes due... Nov 16 2016
Infinity (INFI) Reports Narrower-than-Expected Loss in Q3 Nov 11 2016
Bristol-Myers Squibb Company (BMY), Infinity Pharmaceuticals, Inc. (INFI) Team Up On Opdivo... Nov 10 2016
Blog Coverage Bristol-Myers Squibb and Infinity Pharma Collaborate for Clinical Trials to Test... Nov 10 2016
Edited Transcript of INFI earnings conference call or presentation 9-Nov-16 9:30pm GMT Nov 09 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)